Replies to post #209961 on Biotech Values

[DewDiligence]

With no change in fundamentals, a $600M EV would still be a bargain. Investors are undervaluing both the G/P royalty stream and the (wholly-owned) NASH program, IMO.

Bear in mind that ENTA is cash-flow positive (although just barely) while we wait for G/P approval.